X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1933) 1933
Book Chapter (14) 14
Magazine Article (5) 5
Publication (3) 3
Dissertation (2) 2
Newspaper Article (2) 2
Newsletter (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1780) 1780
science & technology (1441) 1441
life sciences & biomedicine (1426) 1426
female (1167) 1167
male (1036) 1036
enoxaparin - adverse effects (938) 938
enoxaparin - therapeutic use (875) 875
aged (818) 818
anticoagulants - adverse effects (812) 812
middle aged (806) 806
anticoagulants - therapeutic use (708) 708
enoxaparin - administration & dosage (682) 682
enoxaparin (646) 646
anticoagulants - administration & dosage (513) 513
adult (496) 496
cardiovascular system & cardiology (481) 481
treatment outcome (471) 471
anticoagulants (388) 388
abridged index medicus (373) 373
hemorrhage - chemically induced (354) 354
risk factors (333) 333
hematology (330) 330
aged, 80 and over (292) 292
peripheral vascular disease (282) 282
venous thromboembolism - prevention & control (261) 261
thromboembolism (260) 260
cardiac & cardiovascular systems (257) 257
drug therapy (242) 242
heparin (241) 241
surgery (238) 238
prospective studies (227) 227
pharmacology & pharmacy (225) 225
general & internal medicine (224) 224
retrospective studies (222) 222
venous thrombosis - prevention & control (215) 215
heparin - adverse effects (193) 193
heparin - therapeutic use (192) 192
venous thromboembolism (189) 189
medicine, general & internal (188) 188
fibrinolytic agents - therapeutic use (185) 185
thromboembolism - prevention & control (183) 183
postoperative complications - prevention & control (179) 179
time factors (177) 177
drug administration schedule (174) 174
thrombosis (174) 174
fibrinolytic agents - adverse effects (172) 172
fibrinolytic agents - administration & dosage (152) 152
dose-response relationship, drug (151) 151
injections, subcutaneous (151) 151
medicine & public health (151) 151
double-blind method (150) 150
enoxaparin - pharmacology (146) 146
heparin, low-molecular-weight - therapeutic use (139) 139
drug therapy, combination (137) 137
analysis (134) 134
risk assessment (132) 132
venous thromboembolism - etiology (132) 132
low-molecular-weight heparin (130) 130
care and treatment (129) 129
heparin, low-molecular-weight - adverse effects (125) 125
pregnancy (125) 125
health aspects (124) 124
follow-up studies (123) 123
randomized controlled trials as topic (123) 123
myocardial infarction - drug therapy (122) 122
factor xa inhibitors (121) 121
prevention (120) 120
heparin - administration & dosage (119) 119
anticoagulants - pharmacology (115) 115
administration, oral (113) 113
arthroplasty, replacement, knee - adverse effects (113) 113
dosage and administration (113) 113
venous thrombosis - drug therapy (113) 113
venous thrombosis - etiology (112) 112
adolescent (111) 111
incidence (109) 109
rivaroxaban (109) 109
thrombosis - prevention & control (104) 104
heart attacks (103) 103
cardiology (101) 101
pulmonary embolism - prevention & control (101) 101
pulmonary embolism (99) 99
research (99) 99
low molecular weight heparin (98) 98
warfarin - therapeutic use (98) 98
arthroplasty, replacement, hip - adverse effects (93) 93
acute disease (92) 92
heparin, low-molecular-weight - administration & dosage (91) 91
hemorrhage (90) 90
anticoagulation (89) 89
orthopedics (89) 89
bleeding (87) 87
clinical trials (87) 87
internal medicine (86) 86
acute coronary syndromes (84) 84
animals (82) 82
glycosaminoglycans (82) 82
young adult (82) 82
venous thrombosis (81) 81
aspirin - therapeutic use (80) 80
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1877) 1877
Spanish (34) 34
German (23) 23
French (17) 17
Russian (11) 11
Portuguese (7) 7
Chinese (5) 5
Norwegian (5) 5
Polish (5) 5
Italian (4) 4
Czech (3) 3
Danish (2) 2
Serbian (2) 2
Croatian (1) 1
Hebrew (1) 1
Japanese (1) 1
Swedish (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 06/2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 01/2009, Volume 101, Issue 1, pp. 77 - 85
.... Risk ratios (RR) for VTE and bleed end-points were estimated using fixed and random effects meta-analysis... 
anticoagulants | thrombosis | prophylaxis | Embolism | Meta-analysis | Anticoagulants | Thrombosis | Prophylaxis | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Arthroplasty, Replacement, Knee - adverse effects | Humans | Dabigatran | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Clinical Trials, Phase III as Topic | Enoxaparin - administration & dosage | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Drug Administration Schedule | Risk Assessment | Administration, Oral | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Arthroplasty, Replacement, Hip - adverse effects | Venous Thromboembolism - etiology | Hemorrhage - chemically induced | Index Medicus | Administration | Phase III as Topic | Benzimidazoles/administration & dosage/adverse effects/therapeutic use | Pyridines/administration & dosage/adverse effects/therapeutic use | Arthroplasty | Replacement | Oral | Clinical Trials | Kirurgi | Knee/adverse effects | Hemorrhage/chemically induced | Venous Thromboembolism/etiology/mortality/prevention & control | Hip/adverse effects | Anticoagulants/administration & dosage/adverse effects/therapeutic use | Surgery | Enoxaparin/administration & dosage/adverse effects/therapeutic use
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2012, Volume 366, Issue 14, pp. 1287 - 1297
Journal Article
American journal of clinical dermatology, ISSN 1175-0561, 02/2016, Volume 17, Issue 1, pp. 11 - 22
.... The primary outcomes were complete response and time to complete response. The secondary outcomes were partial response, relapse, time to relapse, reduction of itch, the adverse event rate, and withdrawal due to adverse events... 
Life Sciences & Biomedicine | Dermatology | Science & Technology | Antifungal Agents - adverse effects | Glucocorticoids - therapeutic use | Griseofulvin - adverse effects | Photosensitizing Agents - therapeutic use | Humans | Calcitriol - adverse effects | Griseofulvin - therapeutic use | Male | Photosensitizing Agents - adverse effects | Dermatologic Agents - therapeutic use | Ficusin - therapeutic use | Administration, Cutaneous | Enoxaparin - therapeutic use | Calcitriol - therapeutic use | Lichen Planus - drug therapy | Dermatologic Agents - adverse effects | Photochemotherapy | Enoxaparin - adverse effects | Antifungal Agents - therapeutic use | Calcitriol - analogs & derivatives | Fibrinolytic Agents - adverse effects | Fibrinolytic Agents - therapeutic use | Ficusin - adverse effects | Non-Randomized Controlled Trials as Topic | Female | Acitretin - therapeutic use | Lichen Planus - radiotherapy | Acitretin - adverse effects | Glucocorticoids - adverse effects | Sulfasalazine - therapeutic use | Keratolytic Agents - therapeutic use | Lichen Planus - therapy | Keratolytic Agents - adverse effects | Treatment Outcome | Randomized Controlled Trials as Topic | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | PUVA Therapy | Sulfasalazine - adverse effects
Journal Article
The New England journal of medicine, ISSN 1533-4406, 09/2016, Volume 375, Issue 12, pp. 1131 - 1141
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2010, Volume 363, Issue 26, pp. 2499 - 2510
In this clinical trial, rivaroxaban, an oral factor Xa inhibitor, was effective in the initial and continued treatment of symptomatic venous thromboembolism;... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thiophenes - therapeutic use | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Warfarin - adverse effects | Male | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - drug therapy | Warfarin - therapeutic use | Rivaroxaban | Vitamin K - antagonists & inhibitors | Injections, Subcutaneous | Female | Morpholines - adverse effects | Morpholines - therapeutic use | Acute Disease | Double-Blind Method | Venous Thrombosis - drug therapy | Administration, Oral | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Acenocoumarol - adverse effects | Intention to Treat Analysis | Pulmonary Embolism - drug therapy | Acenocoumarol - therapeutic use | Aged | Hemorrhage - chemically induced | Anticoagulants (Medicine) | Thromboembolism | Drug therapy | Health aspects | Risk factors | Anticoagulants | Bone surgery | Veins & arteries | Index Medicus | Abridged Index Medicus | Venous Thrombosis | Factor Xa | Hemorrhage | Life Sciences | Venous Thromboembolism | Thiophenes | Acenocoumarol | Vitamin K | Warfarin | Enoxaparin | Morpholines | Human health and pathology | Pulmonary Embolism | MEDICIN OCH HÄLSOVETENSKAP | Oral | MEDICAL AND HEALTH SCIENCES | Administration | chemically induced | drug therapy | Subcutaneous | antagonists & inhibitors | Injections | adverse effects | therapeutic use
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 388, Issue 10055, pp. 1995 - 2003
Summary Background Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation... 
Internal Medicine | Medicine, General & Internal |